

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**HUTCHMED (China) Limited**

**和黃醫藥（中國）有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 13)**

## **OVERSEAS REGULATORY ANNOUNCEMENT**

This announcement is issued pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

Please refer to the attached announcement which has been published by HUTCHMED (China) Limited on the website of the U.K. Regulatory Information Service on April 30, 2026.

By Order of the Board

**Edith Shih**

*Non-executive Director and Company Secretary*

Hong Kong, April 30, 2026

As at the date of this announcement, the Directors of the Company are:

**Chairman and Non-executive Director:**

Dr Dan ELDAR

**Executive Directors:**

Dr Weiguo SU

*(Chief Executive Officer and  
Chief Scientific Officer)*

Mr CHENG Chig Fung, Johnny

*(Acting Chief Executive Officer and  
Chief Financial Officer)*

**Non-executive Directors:**

Ms Edith SHIH

Ms Ling YANG

**Independent Non-executive Directors:**

Professor MOK Shu Kam, Tony

*(Senior and Lead Independent Non-executive Director)*

Dr Renu BHATIA

Dr Chaohong HU

Professor TAN Shao Weng, Daniel

Mr WONG Tak Wai

## Total Voting Rights

**Hong Kong, Shanghai & Florham Park, NJ — Thursday, April 30, 2026:** HUTCHMED (China) Limited (“[HUTCHMED](#)”) (Nasdaq/AIM: HCM; HKEX: 13) hereby notifies the market that as at April 30, 2026, the issued share capital of HUTCHMED consisted of 872,335,120 ordinary shares of US\$0.10 each, with each share carrying one right to vote and with no shares held in treasury.

The above figure of 872,335,120 may be used by shareholders as the denominator for the calculations by which they could determine if they are required to notify their interest in, or a change to their interest in, HUTCHMED shares under the Financial Conduct Authority’s Disclosure Guidance and Transparency Rules.

For illustrative purposes only, the 872,335,120 ordinary shares would be equivalent to 872,335,120 depositary interests (each equating to one ordinary share) which are traded on AIM or, if the depositary interests were converted in their entirety, equivalent to 174,467,024 American depositary shares (each equating to five ordinary shares) which are traded on Nasdaq.

## About HUTCHMED

HUTCHMED (Nasdaq/AIM: HCM; HKEX: 13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: [www.hutch-med.com](http://www.hutch-med.com) or follow us on [LinkedIn](#).

## CONTACTS

|                                                    |                                                                                                        |
|----------------------------------------------------|--------------------------------------------------------------------------------------------------------|
| <b>Investor Enquiries</b>                          | +852 2121 8200 / <a href="mailto:ir@hutch-med.com">ir@hutch-med.com</a>                                |
| <b>Media Enquiries</b>                             |                                                                                                        |
| FTI Consulting –                                   | +44 20 3727 1030 / <a href="mailto:HUTCHMED@fticonsulting.com">HUTCHMED@fticonsulting.com</a>          |
| Ben Atwell / Tim Stamper                           | +44 7771 913 902 (Mobile) / +44 7779 436 698 (Mobile)                                                  |
| Brunswick – Zhou Yi                                | +852 9783 6894 (Mobile) / <a href="mailto:HUTCHMED@brunswickgroup.com">HUTCHMED@brunswickgroup.com</a> |
| <b>Panmure Liberum</b>                             | <i>Nominated Advisor and Joint Broker</i>                                                              |
| Atholl Tweedie / Emma Earl / Rupert Dearden        | +44 20 7886 2500                                                                                       |
| <b>Cavendish</b>                                   | <i>Joint Broker</i>                                                                                    |
| Geoff Nash / Nigel Birks                           | +44 20 7220 0500                                                                                       |
| <b>Deutsche Numis</b>                              | <i>Joint Broker</i>                                                                                    |
| Freddie Barnfield / Jeffrey Wong / Duncan Monteith | +44 20 7260 1000                                                                                       |